Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC
OncLive,
Tony Mok, MD Results from a final analysis of the phase III KEYNOTE-042 trial have confirmed the benefit of pembrolizumab (Keytru…
102O Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/m…
Overview of attention for article published in Annals of Oncology, April 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 89 Mendeley